Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Kanglin Biotechnology Secures $20 Million Series A Financing to Advance Development of Gene Therapies

Nov 25, 2024•over 1 year ago

Contract Type

partnership

HangzhouBiotechnologyHealth Care

Description

Kanglin Biotechnology has successfully completed a $20 million Series A financing round to support the clinical development of their lead gene therapy asset, KL003, targeting the treatment of beta thalassemia and sickle cell disease. The funding will also be used to evaluate additional therapeutic indications in their pipeline.

Company Information

Company

Kanglin Biotechnology

Location

Hangzhou, Zhejiang, China

About

Kanglin Biotechnology (Hangzhou) Co., Ltd is an innovative biotech company based in Hangzhou, China, focusing on developing the next generation of gene therapies to treat beta thalassemia and sickle cell disease.

Predictive Intelligence
Strategic

ML-powered predictions for Kanglin Biotechnology's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.